We are international
Donate
TEXT SIZE   


Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma

Martha Lacy, MD
Mayo Clinic
Rochester, MN, USA

01.06.15

Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma: Therapy, excluding Transplantation: Treatments For Relapsed/Refractory Disease; AL Amyloidosis

 

Martha Q. Lacy, MD1, Betsy R. LaPlant, MS2*, Kristina M Laumann, BA2*, Shaji Kumar, MD3, Morie A Gertz, M.D.4, Suzanne R Hayman, MD4, Francis Buadi, MD4, Angela Dispenzieri, MD4, John A. Lust, MD, PhD4, Prashant Kapoor, MD4, Nelson Leung, MD5, Stephen J. Russell, MD, PhD4, David Dingli4, Wilson I Gonsalves, MD4*, Rafael Fonseca, M.D.6,7, P. Leif Bergsagel, M.D.8, Vivek Roy, MD9, Taimur Sher, MD10*, Sikander Ailawadhi, MD10*, Asher Chanan-Khan, MD9, A. Keith Stewart, MD11, Craig B. Reeder, MD12, S. Vincent Rajkumar, MD4 and Joseph R. Mikhael, MD13

1Division of Hematology, Department of Internal Medicine, The Mayo Clinic, Rochester, MN
2Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN
3Hematology, Mayo Clinic, Rochester, MN
4Division of Hematology, Mayo Clinic, Rochester, MN
5Nephrology, Mayo Clinic, Rochester, Rochester, MN
6Department of Medicine, Mayo Clinic in Arizona, Scottsdale, AZ
7Division of Hematology - Oncology, Mayo Clinic, Scottsdale, AZ
8Mayo Clinic, Scottsdale, AZ
9Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL
10Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL
11Division of Hematology/Oncology, Research, Mayo Clinic, Scottsdale, AZ
12Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ
13Hematology and Oncology, Mayo Clinic in Arizona, Scottsdale, AZ

 
Background: Pomalidomide is an immunomodulatory agent (IMiD®) that has been approved for treatment of relapsed and refractory multiple myeloma (MM). Combinations of IMiDs and proteasome inhibitors offer the potential for deeper and more durable responses due to enhanced efficacy. Preliminary results of a phase 1 study of twice weekly bortezomib with pomalidomide have been reported with promising results (Richardson, ASH 2012). This phase I/II trial was designed to evaluate the maximum tolerated doses (MTD) as well as safety and efficacy of the combination of pomalidomide, once weekly bortezomib and dexamethasone (PVD) in patients with relapsed, lenalidomide refractory, MM.

 

Patients and methods: We included patients with relapsed MM who had 1-4 prior lines of therapy and were resistant or refractory to lenalidomide. In the phase I portion of the trial, dose level 1 consisted of pomalidomide 4 mg days 1-21 PO, bortezomib 1.0mg/m2 days 1,8,15, and 22 IV or SQ and dexamethasone 40 mg days 1,8,15, and 22 PO, given every 28 days. Bortezomib was increased to 1.3mg/m2 for dose level 2 and and was adopted for the phase 2 portion. The primary aim of the phase I cohort was to determine the MTD of the combination, and for the phase II cohort was to evaluate the confirmed response rate (PR, VGPR, or CR) in relapsed refractory MM.  Response was assessed by the IMWG criteria and toxicity was graded using the CTCAE v4.0.

 

Results: 50 patients were accrued between March 2012 and July 2014 (dose level (DL)1: 3, DL 2: 6, Phase II: 41). We describe results in 47 patients treated at MTD and phase II. Median age was 66, 51% were female and median time from diagnosis to study was 46 months (15-142). Twenty five percent had mSMART defined high-risk status. Median number of prior regimens was 3. All patients had prior lenalidomide, 68% had stem cell transplant, 17% received thalidomide, 56% had alkylators and 57% had bortezomib. With median follow up of 9 months, 72% remain progression free, 96% are alive and 66% remain on treatment. The most common AEs at least possibly attributable to the combination were anemia, fatigue, leukopenia and thrombocytopenia; however, the majority of these were grade 1-2. Grade ≥3 AEs (regardless of attribution) that occurred in at least 3 patients included neutropenia (29), leukopenia (15), lung infection (6), lymphopenia (8) dyspnea (3) and syncope (3). DVT/PE occurred in one patient. Among the 42 patients who were evaluable, confirmed responses (PR, VGPR, or CR) were seen in 34 (81%) including sCR (3), CR (5), VGPR (8), PR (18). Confirmed responses were seen in 9 of 11( 82%) high risk patients. Median progression free survival was 17.7 months (95%CI: 9.5-NA).

 

Conclusions: PVD is a highly effective combination in patients refractory to lenalidomide with confirmed responses in over 80%.  Weekly administration of bortezomib enhanced the tolerability and convenience of this regimen. Toxicities are manageable, mostly consisting of mild cytopenias with no significant neuropathy or DVT. PVD is a highly attractive option in patients with relapsed and refractory MM.


 related articles
ASH 2014: Dr. Jeffre...
ASH 2014: Dr. Keith ...
ASH 2014: Dr. Ravi V...
ASH 2014: Dr. Shaji ...
Diffusion-Weighted M...
Evaluation of Curren...
Hevylite® to Monitor...
Hevylite® to Monitor...
In Multiple Myeloma,...
Landscape of Driver ...
PET-CT Has Major Dia...
The Presence of FDG ...
Utility of Serum Fre...
Whole-Body Reduced-D...
Connect MM®—the Mult...
Final Results from t...
Impact of Beta Block...
Meta-Analysis of Pha...
Oprozomib and Dexame...
Car-Bird [Carfilzomi...
Carfilzomib, Lenalid...
Carfilzomib, Lenalid...
Connect MM®—the Mult...
Long-Term Ixazomib M...
Long-Term Outcome of...
Phase I Study of the...
Pomalidomide, Bortez...
A Phase I Trial of P...
Carfilzomib, Lenalid...
Leopard: A Phase II ...
Myeloma Minute
...

Pomalidomide Plus Lo...
Pomalidomide, Cyclop...
Safety and Efficacy ...
SWOG 1211: Initial R...
The Combination of B...
Three Drug Combinati...
Adverse Cytogenetics...
Autologous Followed ...
Prospective Molecula...
A Phase I Study of H...
Pomalidomide, Cyclop...
A Phase Ib Dose Esca...
Safety and Efficacy ...
Safety and Efficacy ...
Serum Free Light Cha...
Utility of Serum Fre...
Critical Issues Need...
News Briefing: The L...
The IMWG Conference ...
ASH 2014 Social Medi...

ASH 2014: Dr. Jeffrey Zonder's Overview
ASH 2014: Dr. Keith Stewart's Overview
ASH 2014: Dr. Ravi Vij's Overview
ASH 2014: Dr. Shaji Kumar's Overview
Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma
Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic
Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma
Hevylite® to Monitor Response to Therapy in Multiple Myeloma
In Multiple Myeloma, High-Risk Features Are Modulated By Other Chromosomal changes : A Large Snparray IFM Study
Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response
PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma
The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease
Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response
Whole-Body Reduced-Dose CT as Primary Staging and During Follow-up in First-Line Treatment of Transplant-Eligible Multiple Myeloma Patients: Results of the German GMMG-MM5 Trial
Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma
Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients
Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma
Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study
Car-Bird [Carfilzomib, Clarithromycin(Biaxin®), Lenalidomide/(Revlimid®), Dexamethasone) for Newly-Diagnosed Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease
Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)
Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma
A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments
Myeloma Minute
March 5, 2015
Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study
Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma
SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)
The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma
Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment
Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy
Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma
Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma
A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial
Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response
Critical Issues Need Answers:
Providing Best Options for Myeloma Treatments in 2014
News Briefing: The Latest on Blood Cancers – From Advances to Patient Advantages
The IMWG Conference Series "Making Sense of Treatment"
56th ASH Annual Meeting | Dec. 8, 2014
ASH 2014 Social Media Team


You might also be interested in:

Overviews
ASH 2014: Dr. Jeffrey Zonder's Overview

Jeffrey Zonder, MD
Karmanos Cancer Institute
Wayne State University
Detroit, MI, USA

 


ASH 2014: Dr. Keith Stewart's Overview
Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ, USA

ASH 2014: Dr. Ravi Vij's Overview
Ravi Vij, MD
Washington University School of Medicine
St. Louis, MO, USA

ASH 2014: Dr. Shaji Kumar's Overview

Shaji Kumar, MD
Professor of Medicine, Division of Hematology
Mayo Clinic, Rochester, MN


Diagnostics, Genetics, Other Research
Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma

Evangelos Terpos, MD
Department of Clinical Therapeutics
National and Kapodistrian University of Athens
School of Medicine
Athens, Greece


Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic

Roman Hajek, MD
University of Ostrava
Ostrava, Czech Republic


Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma

Xavier Leleu, MD
Hopital Claude Huriez
CHRU Lille
Lille, France


Hevylite® to Monitor Response to Therapy in Multiple Myeloma

Xavier Leleu, MD
Hopital Claude Huriez
CHRU Lille
Lille, France


In Multiple Myeloma, High-Risk Features Are Modulated By Other Chromosomal changes : A Large Snparray IFM Study

Jill Corre, MD
Unité de Génomique du Myélome
Toulouse, France


Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response

David Tamborero, PhD
Institute for Molecular Medicine Finland (FIMM)
University of Helsinki
Helsinki, Finland


PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma

Brittany Dykstra, MD
Mayo Clinic
Rochester, MN, USA


The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

Elena Zamagni, MD
Seràgnoli Institute of Hematology
Bologna University School of Medicine
Bologna, Italy


Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response

Muhamad Alhaj Moustafa, MD
Mayo Clinic
Rochester, MN


Whole-Body Reduced-Dose CT as Primary Staging and During Follow-up in First-Line Treatment of Transplant-Eligible Multiple Myeloma Patients: Results of the German GMMG-MM5 Trial

Katja Weisel, MD
University Hospital Tubingen
Tubingen, Germany


Other Novel Agents
Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Jatin Shah, MD
MD Anderson Cancer Center
Houston, TX, USA


Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma

Heinz Ludwig, MD
Wilhelminenspital
Vienna, Austria


Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients

Yi Lisa Hwa, DNP
Mayo Clinic
Rochester, MN, USA


Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma

Parameswaran N. Hari, MD
Medical College of Wisconsin
Milwaukee, WI


Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study

Parameswaran N. Hari, MD
Department of Medicine
Medical College of Wisconsin
Milwaukee, WI, USA


Proteosome Inhibitors
Car-Bird [Carfilzomib, Clarithromycin(Biaxin®), Lenalidomide/(Revlimid®), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Tomer Mark, MD
Weill Cornell Medical College
New York, NY, USA


Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study

Ola Landgren, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY, USA


Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ, USA


Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Jatin Shah, MD
MD Anderson Cancer Center
Houston, TX, USA


Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Shaji Kumar, MD
Mayo Clinic,
Rochester, MN, USA


Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Giampaolo Merlini, MD
IRCCS Policlinico San Matteo
University of Pavia
Pavia, Italy


Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Jonathan Kaufman, MD
Winship Cancer Institute
Emory University
Atlanta, GA, USA


Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma

Martha Lacy, MD
Mayo Clinic
Rochester, MN, USA


Immunomodulatory Agents
A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

Jeffrey Zonder, MD
Karmanos Cancer Institute
Wayne State University
Detroit, MI, USA


Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ, USA


Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Andrew Spencer, MD
Alfred Hospital-Monash University
Melbourne, Australia


Myeloma Minute
March 5, 2015

Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses

Martha Lacy, MD
Mayo Clinic
Rochester, MN, USA


Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Rachid Baz, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL, USA
 


Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma

Meletios A. Dimopoulos, MD
Department of Clinical Therapeutics
University of Athens School of Medicine
Athens, Greece


SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)

Saad Usmani, MD
Levine Cancer Institute
Charlotte, NC, USA


The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma

Evangelos Terpos, MD
Department of Clinical Therapeutics
National and Kapodistrian University of Athens
School of Medicine
Athens, Greece


Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Meletios Dimopoulos, MD
Department of Clinical Therapeutics
National and Kapodistrian University of Athens School of Medicine
Athens, Greece


Transplantation
Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy

Gregory P. Kaufman, MD
Mayo Clinic
Rochester, MN, USA


Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma

Stefan Knop, MD
Wuerzburg University Medical Center
Wuerzburg, Germany


Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma

Benedetto Bruno, MD
University of Torino
Torino, Italy

 


Alkylating Agents
A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma

Emma Scott, MD
Knight Cancer Institute
Oregon Health and Science University
Portland, OR, USA


Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Rachid Baz, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL, USA
 


Anti-CD38 Agents
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Thomas G. Martin, MD
University of California San Francisco
San Francisco, CA, USA


Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma

Meletios A. Dimopoulos, MD
Department of Clinical Therapeutics
University of Athens School of Medicine
Athens, Greece


Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Torben Plesner, MD
Vejle Hospital
Vejle, Denmark

Serum Free Light Chains
Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial

Jill Corre, MD
Unité de Génomique du Myélome
Toulouse, France


Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response

Muhamad Alhaj Moustafa, MD
Mayo Clinic
Rochester, MN


Events
Critical Issues Need Answers:
Providing Best Options for Myeloma Treatments in 2014

Friday, Dec. 5, 2014
12:00pm PT
Moscone Center
San Francisco, California


News Briefing: The Latest on Blood Cancers – From Advances to Patient Advantages
Sunday, Dec. 7, 2014
8:00pm PT
San Francisco, California

The IMWG Conference Series "Making Sense of Treatment"
56th ASH Annual Meeting | Dec. 8, 2014
  • ASH Oral and Posters Overview and High Risk Smoldering MM
  • Frontline Therapy
  • Role of MRD
  • Transplant
  • Maintenance / Continous Therapy
  • Imaging
  • Relapse and New Drugs

Social Media Team
ASH 2014 Social Media Team
Tune in as the IMF brings myeloma support group leaders and patients to San Francisco for the 56th annual meeting of the American Society of Hematology (ASH), an exciting convergence of 20,000 health care professionals from around the world. Start following the IMF ASH team members now on social media as they ramp up to share the latest clinical updates in myeloma research, therapies, and practice strategies via Twitter (#IMFASH2014), Facebook, blogs and videos.